Insight journal - Dealtalk

Will Allergan and Forest bid for Elan?

Posted on 17 July 2013

Tags: , , , ,

Sources suggest that Allergan and Forest will table rival bids to acquire Elan this week.

Other companies such as Mylan International and Endo Health Solutions Inc, which took a preliminary look at Elan, are no longer involved in the process, they added.

All the people asked not to be named because the matter is not public. Allergan, Forest and Elan declined to comment. Endo and Mylan did not immediately respond to requests for comment.

In June, Elan, which has a market capitalization of $7 billion, rejected a hostile bid by US-based investment firm Royalty Pharma worth up to $8 billion. Instead, the company put itself up for sale.

Companies like Allergan and Forest are interested in Elan primarily for the tax savings that come from being domiciled in Ireland, where the corporate tax rate is 12.5 percent, the people familiar with the matter said.

Some Elan investors have speculated that any of the industry buyers could acquire Elan and sell a portion of the royalties on the drugmaker's multiple sclerosis drug Tysabri to Royalty Pharma, which is what the investment firm has wanted all along.

With such a deal, Royalty would get the Tysabri royalties, the industry buyer would get a lower corporate tax rate and Elan would get a better price for the company. It is unclear if any such discussions are under way, however.

Read the full story at Reuters



Read: more on Elan company profile, recent partnering, M&A and financing news and articles

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply